OTLK
Outlook Therapeutics Inc
Halal Rating :
Last Price
$2.14
Last updated:
Market Cap
-
7D Change
-6.55%
1 Year Change
529.41%
Company Overview
Industries
Exchange
Next Earnings Date
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-vikg), an ophthalmic formulation of bevacizumab for use in retinal indications. The company's primary focus is on treating wet age-related macular degeneration (wet AMD) and other retinal diseases.
The company is currently in the development phase and has not yet generated revenue from its products. Their lead product candidate is still seeking FDA approval.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Outlook Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.